These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38104995)

  • 21. Pancreatitis as immune-related adverse event during pembrolizumab therapy for multiple lung metastases from renal pelvic cancer.
    Kokura K; Watanabe J; Takuma T; Yokozeki H; Uketa S; Uemura Y
    IJU Case Rep; 2023 Nov; 6(6):402-405. PubMed ID: 37928307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study Protocol.
    Kogure Y; Hashimoto H; Oki M
    Clin Lung Cancer; 2021 Nov; 22(6):e921-e924. PubMed ID: 34053861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
    Gadgeel SM; Stevenson JP; Langer CJ; Gandhi L; Borghaei H; Patnaik A; Villaruz LC; Gubens M; Hauke R; Yang JC; Sequist LV; Bachman R; Saraf S; Raftopoulos H; Papadimitrakopoulou V
    Lung Cancer; 2018 Nov; 125():273-281. PubMed ID: 30429032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study.
    Yoon SY; Han JJ; Baek SK; Kim HJ; Maeng CH
    Lung Cancer; 2020 Sep; 147():21-25. PubMed ID: 32652370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
    Li D; He C; Xia Y; Du Y; Zhang J
    J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safe Concurrent Use of Anti-tuberculosis Drugs and Pembrolizumab in a Patient with Non-small-cell Lung Cancer Who Was Infected with Mycobacterium tuberculosis.
    Nakahama K; Kaneda H; Ogawa K; Matsumoto Y; Tani Y; Suzumura T; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
    Intern Med; 2022; 61(7):1039-1042. PubMed ID: 35370247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report.
    Sumi T; Koshino Y; Michimata H; Nagayama D; Watanabe H; Yamada Y; Chiba H
    Transl Lung Cancer Res; 2022 Sep; 11(9):1973-1976. PubMed ID: 36248324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency.
    Sonehara K; Tateishi K; Hirabayashi T; Araki T; Ikuyama Y; Machida R; Hanaoka M
    Case Rep Oncol; 2021; 14(1):1-7. PubMed ID: 33613234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late-onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer.
    Ichihara S; Kunishige M; Kadota N; Okano Y; Machida H; Hatakeyama N; Naruse K; Shinohara T; Takeuchi E
    Thorac Cancer; 2023 Jan; 14(1):81-84. PubMed ID: 36411591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-related cytokine release syndrome in a treatment-naïve patient with lung adenocarcinoma: A case report.
    Deng PB; Jiang J; Hu CP; Cao LM; Li M
    World J Clin Cases; 2022 Feb; 10(5):1580-1585. PubMed ID: 35211595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
    Borghaei H; Langer CJ; Gadgeel S; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Saraf S; Keller SM; Gandhi L
    J Thorac Oncol; 2019 Jan; 14(1):124-129. PubMed ID: 30138764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune-related colitis and pancreatitis treated with infliximab.
    Ohwada S; Ishigami K; Yokoyama Y; Kazama T; Masaki Y; Takahashi M; Yoshii S; Yamano HO; Chiba H; Nakase H
    Clin J Gastroenterol; 2023 Feb; 16(1):73-80. PubMed ID: 36414888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer.
    Afzal MZ; Dragnev K; Shirai K
    J Thorac Dis; 2018 Jun; 10(6):3575-3584. PubMed ID: 30069355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer.
    Yomota M; Mirokuji K; Sakaguchi M; Kitahara Y; Chin F; Setoguchi K; Hosomi Y
    Intern Med; 2021 Nov; 60(21):3459-3462. PubMed ID: 33775995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
    Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
    Respir Med Case Rep; 2022; 40():101773. PubMed ID: 36408484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
    Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
    Respir Med Case Rep; 2022; 40():101753. PubMed ID: 36217354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psoriasis induced by first‑line pembrolizumab in metastatic non‑small cell lung cancer: A case report.
    Gatti F; Caruso G; Potenza C; Santini D; Petrozza V; Annetta A; Ceddia S; Cosimati A; Brandi M; Sorrentino V; Proietti I; Rossi L
    Oncol Lett; 2023 Jul; 26(1):311. PubMed ID: 37332334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.